USANA Health Sciences, Inc. (NYSE:USNA) updated its FY17 earnings guidance on Tuesday. The company provided earnings per share guidance of about $3.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.79. The company issued revenue guidance of $1.03 billion, compared to the consensus revenue estimate of $1.03 billion.

USANA Health Sciences, Inc. (NYSE:USNA) traded up 1.47% during trading on Tuesday, hitting $61.95. The stock had a trading volume of 163,700 shares. USANA Health Sciences, Inc. has a 1-year low of $52.55 and a 1-year high of $72.95. The company has a market capitalization of $1.51 billion, a P/E ratio of 16.09 and a beta of 1.09. The stock’s 50-day moving average price is $58.59 and its 200-day moving average price is $60.42.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $0.98 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.08). USANA Health Sciences had a return on equity of 28.93% and a net margin of 9.47%. The firm had revenue of $257.10 million during the quarter, compared to analysts’ expectations of $273.61 million. During the same quarter in the previous year, the firm earned $2.07 earnings per share. USANA Health Sciences’s revenue was down .5% on a year-over-year basis. Analysts expect that USANA Health Sciences, Inc. will post $3.79 earnings per share for the current year.

USANA Health Sciences announced that its board has approved a share repurchase program on Tuesday, July 25th that authorizes the company to repurchase $64.60 million in shares. This repurchase authorization authorizes the company to buy up to 46% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

A number of equities research analysts have commented on USNA shares. Pivotal Research cut their target price on shares of USANA Health Sciences from $75.00 to $70.00 and set a buy rating for the company in a research report on Wednesday, July 26th. BidaskClub downgraded shares of USANA Health Sciences from a sell rating to a strong sell rating in a research report on Monday, July 31st.

In other news, Director Myron W. Wentz sold 40,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $56.59, for a total transaction of $2,263,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert A. Fuller sold 1,483 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $57.67, for a total transaction of $85,524.61. Following the sale, the director now directly owns 1,483 shares of the company’s stock, valued at approximately $85,524.61. The disclosure for this sale can be found here. In the last three months, insiders have sold 386,340 shares of company stock valued at $22,270,913. Insiders own 53.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with's FREE daily email newsletter.